|
pmiCME Updates Track 1 |
|
To date, the following organizations have provided educational grants in support of pmiCME Updates
Track 1: Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners, Genzyme, a Sanofi company, Novo Nordisk Inc. and Vertex Pharmaceuticals Incorporated and Genentech.
|
| 7:50 AM-8:00 AM |
Breakfast
|
| 8:00 AM-9:15 AM |
Understanding the Impact of HCV and Therapeutic Considerations for the Front-Line Provider
Learning Objectives:
- Identify and screen patients at risk for HCV infection and counsel patients accordingly
- Illustrate knowledge gained on new triple-combination therapy combinations that include DAAs and collaborate with HCV specialist in the treatment of patients with chronic hepatitis C
- Monitor HCV patients on DAA therapy for potential adverse events, drug interactions, and issues relating to drug adherence
Paul Kwo, MD , Professor of Medicine,
Medical Director of Liver Transplantation,
Indiana University School of Medicine,
Indianapolis, IN
Stephen A Harrison, MD, MC , Clinical Associate Professor of Medicine,
University of Texas Health Science Center,
San Antonio, TX
|
| 9:15 AM-9:45 AM |
AM Break
|
| 9:45 AM-11:00 AM |
Defining the Role of Intra-articular Injections in the Management of Knee Osteoarthritis Pain
Learning Objectives:
- Explain the pathophysiology of OA of the knee and how current treatment options may affect various pain pathways and/or the potential for disease modification
- Consider individual patient and treatment characteristics (e.g., comorbidities, stage of disease, level of pain, drug tolerability, previous response to treatment) when initiating a multi-modal treatment plan for patients with knee OA
- Describe the individual clinical and patient characteristics that guide the selection of intraarticular corticosteroid and HA injection therapy
- Compare and contrast the clinical utility of intra-articular corticosteroids and/or HA injection therapy
James W. McNabb, MD , FAAFP , Adjunct Associate Professor,
Piedmont Healthcare,
Mooresville, NC, Department of Family Medicine,
University of North Carolina ,
Chapel Hill, NC
|
| 11:00 AM-12:15 PM |
Lunch
|
| 12:15 PM-1:45 PM |
Insulin 101: An Introduction to Insulin Therapy in the 21st Century
Learning Objectives:
- Calculate appropriate insulin doses for initiating basal and basal-prandial insulin regimens in T2DM
- Demonstrate best practices in insulin injection and SMBG techniques to improve treatment adherence and potentially impact patient outcomes
- Apply pattern recognition to SMBG data to appropriately titrate insulin doses and adjust insulin regimens to specific patient needs
- Summarize the efficacy and safety findings from clinical trials of investigational insulins and the combination of incretin-based therapies with insulin
Etie Moghissi, MD, FACE , Associate Clinical Professor of Medicine,
University of California Los Angles,
Marina del Rey, CA
Javier Morales, MD Advanced Internal Medicine Group,
New Hyde Park, NY
Debbie Hinnen, ARNP , BC-ADM , FAAN , Director of Education Services,
Mid-America Diabetes Associates,
Wichita, KS
|
| 1:45 PM-1:55 PM |
PM Break
|
| 1:55 PM-3:10 PM |
Highlights from the Medical Literature
Learning Objectives:
- Critically analyze findings from key studies that have recently been published in the medical literature
- Apply appropriate strategies to your screening, assessment and management practices based on updates published in the recent medical literature
John J. Russell, MD
( Read Bio)
, Clinical Associate Professor,
Family and Community Medicine,
Temple University School of Medicine,
Philadelphia, PA, , Associate Director,
Family Medicine Residency Program,
Abington Memorial Hospital,
Abington, PA |
| 3:10 PM-4:25 PM |
Targeting the Kidney in Managing the Patient with Type 2 Diabetes: A New Approach
Learning Objectives:
- Discuss the role of the kidney in glucose homeostasis
- Describe the contribution of the kidney to the sustained elevated glucose levels observed in individuals with uncontrolled type 2 diabetes.
- Explain the mechanism of action of therapies that act through the kidney to reduce hyperglycemia in type 2 diabetes
- Assess clinical efficacy and safety data, and identify the potential place of therapies that target the kidney in the management of type 2 diabetes
William T. Cefalu, MD , Douglas L. Manship Professorship in Diabetes,
Louisiana State University,
New Orleans, LA, , Professor, Chief,
Nutrition/Chronic Disease,
Pennington Biomedical Research Center,
Baton Rouge, LA
Eugenio Cersosimo, PhD , MD , Associate Professor of Medicine,
Medical Director of Clinical Research,
Texas Diabetes Institute,
University of Texas Health Science Center at San Antonio,
San Antonio, TX
|
|
pmiCME Updates Track 2 |
|
To date, the following organizations have provided educational grants in support of pmiCME Updates
Track 2: Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through a collaboration with Eli Lilly and Company, Forest Research Institute, a subsidiary of Forest Laboratories, Inc., and Ironwood Pharmaceuticals., Gilead Sciences Medical Affairs, sanofi-aventis U.S. and Shire.
|
| 7:50 AM-8:00 AM |
Breakfast
|
| 8:00 AM-9:30 AM |
Managing Cardiometabolic Disease in Patients With, or at Risk for, Type 2 Diabetes
Learning Objectives:
- Assess CVD risk factors in patients with T2DM and establish individualized treatment goals for comprehensive patient management
- Evaluate the therapeutic profiles of incretin-based therapies and the safe use of these agents, alone or in combination with other antihyperglycemic agents
- Identify patients that would benefit from insulin therapy and select insulin regimens that would best provide postprandial insulin replacement
Scott V. Joy, MD, CDE, FACP , Chief of Clinical Services,
Division of General Internal Medicine,
Medical Director,
Duke Health Center at Pickett Road,
Durham, NC
Michael E. Cobble, MD , Private Practice,
Family Medicine,
Director,
Canyons Medical Center,
Sandy, UT
Jeffery S Freeman Philadelphia College of Osteopathic Medicine,
Philadelphia, PA
|
| 9:30 AM-10:00 AM |
AM Break
|
| 10:00 AM-11:15 AM |
Management of Diverticular Disease: New Strategies, New Approaches
Learning Objectives:
- Characterize the patterns of prevalence and risk factors for diverticular disease
- Integrate diagnostic approaches into the evaluation of patients with diverticular disease
- Formulate and apply appropriate medical management strategies when indicated for the treatment and prevention of diverticulitis
- Incorporate patient counseling approaches regarding indications for elective surgical intervention
Sita Chokhavatia, MD Mount Sinai School of Medicine,
New York, NY
Martin H Floch, MD , MACG , AGAF , Clinical Professor of Medicine,
Digestive Disease Section,
Yale University School of Medicine,
New Haven, CT
|
| 11:15 AM-12:30 PM |
Lunch
|
| 12:30 PM-1:45 PM |
SCALE HBV (Screening, Counseling, Linkage to Care Education)
Learning Objectives:
- Apply the guidelines for HBV screening in appropriate at-risk populations
- Develop tactics to overcome patient objections to HBV screening, treatment, and/or vaccination
- Demonstrate how to correctly interpret screening results
- Appropriately manage HBV patients with respect to treatment, monitoring, and/or referral
Tram T Tran, MD , Medical Director, Liver Transplantation,
Cedars-Sinai Medical Center,
Associate Professor of Medicine,
UCLA,
Los Angeles, CA
Hannah M Lee, MD , Assistant Professor of Medicine,
Tufts University School of Medicine,
Boston, MA, , Director, Asian-Pacific Liver Wellness Program,
Tufts Medical Center,
Boston, MA
|
| 1:45 PM-2:00 PM |
PM Break
|
| 2:00 PM-3:30 PM |
Evidence Based Strategies to Improve Glycemic Control in Type 2 Diabetes
Learning Objectives:
- Apply current data from clinical trials for A1C goal setting and individualization of treatment
- Recognize the importance of timely initiation of drug therapy including the early insulin initiation in reducing the complications of type 2 diabetes
- Describe interdisciplinary team and collaborative care approaches that can improve clinical outcomes
- Identify and implement strategies for overcoming the barriers to insulin initiation and medication adherence.
Andrew Ahmann, MD , Professor of Medicine and Director,
Harold Schnitzer Diabetes Health Center,
Oregon Health Sciences University,
Portland, OR
Dace L Trence, MD, FACE , Director,
Diabetes Care Center,
Associate Professor Division of Metabolism, Endocrinology and Nutrition,
University of Washington Medical Center,
Seattle, WA
|
| 3:30 PM-5:00 PM |
Getting Back on Track: Improving IBS Assessment and Management in Primary Care
Learning Objectives:
- Recognize the symptoms and accurately diagnose patients who have IBS
- Implement strategies to overcome barriers in diagnosing and treating patients with IBS
- Compare the safety and efficacy of currently available treatments when selecting therapy for patients with IBS
- Explain novel agents in development for the treatment of IBS and their potential implications for practice
Lawrence R. Schiller, MD, FACG
( Read Bio)
, Program Director,
Gastroenterology Fellowship,
Baylor University Medical Center,
Dallas, TX Lucinda A. Harris, MD, MS , Associate Professor of Medicine,
Mayo School of Medicine,
Scottsdale, AZ
|
